Mitochondrial Regulation of Inflammasome Activation in Chronic Obstructive Pulmonary Disease

Journal of Innate Immunity

Volumn 8, Issue 2, 2016, Pages 121-128

  Yoon, Chang Min ^a   Nam, Milang ^a   Oh, Yeon Mok ^b   Dela Cruz, Charles S ^a   Kang, Min Jong ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Chronic obstructive pulmonary disease; Inflammasome; Mitochondria; Mitochondrial antiviral signaling protein; NLRX1

Indexed keywords

INFLAMMASOME; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; NLRX1 PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DEATH; CELL DIFFERENTIATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFORMATIONAL TRANSITION; HUMAN; INFLAMMATION; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; MITOCHONDRION; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; IMMUNOLOGY; PATHOLOGY; SMOKING;

ANIMALS; HUMANS; IMMUNITY, INNATE; INFLAMMASOMES; INFLAMMATION; MITOCHONDRIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIGNAL TRANSDUCTION; SMOKING;

EID: 84946811502     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000441299     Document Type: Review

References (59)

1. Senior RM, Shapiro SD: Chronic obstructive pulmonary disease: epidemiology, pathophysiology, and pathogenesis; in Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR, Senior RM (eds): Fishman's Pulmonary Diseases and Disorders. New York, McGraw-Hill, 1998, pp 659-681.
2. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555.
3. Decramer M, Janssens W, Miravitlles M: Chronic obstructive pulmonary disease. Lancet 2012;379:1341-1351.
4. Chung KF, Adcock IM: Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008;31:1334-1356.
5. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
6. Bhalla DK, Hirata F, Rishi AK, Gairola CG: Cigarette smoke, inflammation, and lung injury: a mechanistic perspective. J Toxicol Environ Health B Crit Rev 2009;12:45-64.
7. Hogg JC, Timens W: The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009;4:435-459.
8. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA: Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411-415.
9. Anthonisen NR, Connett JE, Enright PL, Manfreda J: Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-339.
10. Nussbaumer-Ochsner Y, Rabe KF: Systemic manifestations of COPD. Chest 2011;139:165-173.
11. Kang MJ, Yoon CM, Kim BH, et al. Suppression of NLRX1 in chronic obstructive pulmonary disease. J Clin Invest 2015;125:2458-2462.
12. An inflammatory assemblage. Nat Immunol 2012;13:320.
13. Strowig T, Henao-Mejia J, Elinav E, Flavell R: Inflammasomes in health and disease. Nature 2012;481:278-286.
14. Davis BK, Wen H, Ting JP: The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 2011;29:707-735.
15. Schroder K, Tschopp J: The inflammasomes. Cell 2010;140:821-832.
16. Kang MJ, Homer RJ, Gallo A, et al. IL-18 is induced and IL-18 receptor alpha plays a critical role in the pathogenesis of cigarette smoke-induced pulmonary emphysema and inflammation. J Immunol 2007;178:1948-1959.
17. Eltom S, Stevenson CS, Rastrick J, et al. P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke. PLoS One 2011;6:e24097.
18. Lommatzsch M, Cicko S, Muller T, et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:928-934.
19. Dima E, Koltsida O, Katsaounou P, et al. Implication of interleukin (IL)-18 in the pathogenesis of chronic obstructive pulmonary disease (COPD). Cytokine 2015;74:313-317.
20. Brusselle GG, Provoost S, Bracke KR, Kuchmiy A, Lamkanfi M: Inflammasomes in respiratory disease: from bench to bedside. Chest 2014;145:1121-1133.
21. Weinberg SE, Sena LA, Chandel NS: Mitochondria in the regulation of innate and adaptive immunity. Immunity 2015;42:406-417.
22. Green DR, Galluzzi L, Kroemer G: Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science 2011;333:1109-1112.
23. Nunnari J, Suomalainen A: Mitochondria: in sickness and in health. Cell 2012;148:1145-1159.
24. Tschopp J: Mitochondria: sovereign of inflammation? Eur J Immunol 2011;41:1196-1202.
25. Gurung P, Lukens JR, Kanneganti TD: Mitochondria: diversity in the regulation of the NLRP3 inflammasome. Trends Mol Med 2015;21:193-201.
26. Galluzzi L, Kepp O, Kroemer G: Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012;13:780-788.
27. Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol 2004;4:499-511.
28. Kawai T, Akira S: Innate immune recognition of viral infection. Nat Immunol 2006;7:131-137.
29. Seth RB, Sun L, Ea CK, Chen ZJ: Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF 3. Cell 2005;122:669-682.
30. Arnoult D, Soares F, Tattoli I, Girardin SE: Mitochondria in innate immunity. EMBO Rep 2011;12:901-910.
31. Belgnaoui SM, Paz S, Hiscott J: Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. Curr Opin Immunol 2011;23:564-572.
32. Kang MJ, Lee CG, Lee JY, et al. Cigarette smoke selectively enhances viral PAMP-and virus-induced pulmonary innate immune and remodeling responses in mice. J Clin Invest 2008;118:2771-2784.
33. Subramanian N, Natarajan K, Clatworthy MR, Wang Z, Germain RN: The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell 2013;153:348-361.
34. Cai X, Chen J, Xu H, et al. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell 2014;156:1207-1222.
35. Arnoult D, Soares F, Tattoli I, Castanier C, Philpott DJ, Girardin SE: An N-terminal addressing sequence targets NLRX1 to the mitochondrial matrix. J Cell Sci 2009;122:3161-3168.
36. Moore CB, Bergstralh DT, Duncan JA, et al. NLRX1 is a regulator of mitochondrial antiviral immunity. Nature 2008;451:573-577.
37. Allen IC, Moore CB, Schneider M, et al. NLRX1 protein attenuates inflammatory responses to infection by interfering with the RIG-I-MAVS and TRAF6-NF-κB signaling pathways. Immunity 2011;34:854-865.
38. Hong M, Yoon SI, Wilson IA: Structure and functional characterization of the RNA-binding element of the NLRX1 innate immune modulator. Immunity 2012;36:337-347.
39. Xia X, Cui J, Wang HY, et al. NLRX1 negatively regulates TLR-induced NF-κB signaling by targeting TRAF6 and IKK. Immunity 2011;34:843-853.
40. Lei Y, Wen H, Yu Y, et al. The mitochondrial proteins NLRX1 and TUFM form a complex that regulates type I interferon and autophagy. Immunity 2012;36:933-946.
41. Parvatiyar K, Cheng G: NOD so fast: NLRX1 puts the brake on inflammation. Immunity 2011;34:821-822.
42. Abdul-Sater AA, Said-Sadier N, Lam VM, et al. Enhancement of reactive oxygen species production and chlamydial infection by the mitochondrial Nod-like family member NLRX1. J Biol Chem 2010;285:41637-41645.
43. Rebsamen M, Vazquez J, Tardivel A, Guarda G, Curran J, Tschopp J: NLRX1/NOD5 deficiency does not affect MAVS signalling. Cell Death Differ 2011;18:1387.
44. Vlahos R, Bozinovski S: Role of alveolar macrophages in chronic obstructive pulmonary disease. Front Immunol 2014;5:435.
45. Davies LC, Jenkins SJ, Allen JE, Taylor PR: Tissue-resident macrophages. Nat Immunol 2013;14:986-995.
46. van oud Alblas AB, van Furth R: Origin, kinetics, and characteristics of pulmonary macrophages in the normal steady state. J Exp Med 1979;149:1504-1518.
47. Franke-Ullmann G, Pfortner C, Walter P, Steinmuller C, Lohmann-Matthes ML, Kobzik L: Characterization of murine lung interstitial macrophages in comparison with alveolar macrophages in vitro. J Immunol 1996;157:3097-3104.
48. Thepen T, Van Rooijen N, Kraal G: Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice. J Exp Med 1989;170:499-509.
49. Matzinger P: Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
50. Matzinger P: The danger model: a renewed sense of self. Science 2002;296:301-305.
51. Rock KL, Latz E, Ontiveros F, Kono H: The sterile inflammatory response. Annu Rev Immunol 2010;28:321-342.
52. Eltom S, Belvisi MG, Stevenson CS, et al. Role of the inflammasome-caspase1/11-IL-1/18 axis in cigarette smoke driven airway inflammation: an insight into the pathogenesis of COPD. PLoS One 2014;9:e112829.
53. Pauwels NS, Bracke KR, Dupont LL, et al. Role of IL-1α and the Nlrp3/caspase-1/IL-1β axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur Respir J 2011;38:1019-1028.
54. Ferhani N, Letuve S, Kozhich A, et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:917-927.
55. Kanazawa H, Tochino Y, Asai K, Ichimaru Y, Watanabe T, Hirata K: Validity of HMGB1 measurement in epithelial lining fluid in patients with COPD. Eur J Clin Invest 2012;42:419-426.
56. Lu B, Nakamura T, Inouye K, et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012;488:670-674.
57. Tuder RM, Petrache I, Elias JA, Voelkel NF, Henson PM: Apoptosis and emphysema: the missing link. Am J Respir Cell Mol Biol 2003;28:551-554.
58. Taraseviciene-Stewart L, Voelkel NF: Molecular pathogenesis of emphysema. J Clin Invest 2008;118:394-402.
59. MacNee W: Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:50-60.